Partners Brian Carey, Hathaway Russell and associate Igor Gorlach will present at this event for professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related products
Foley Hoag LLP partners Brian Carey and Hathaway Russell and associate Igor Gorlach will take part in the DIA 2013 - 49th Annual Meeting at the Boston Convention and Exhibition Center from June 23-27.
Tuesday, June 25, 4:00 - 5:30 p.m.
“Bringing the Views of “Payer Regulators” into Product Development to Align Label Outcomes and Safety with Patient Access”
This session will discuss how data requirements of payer regulators post-approval can be different than the needs of regulators working on product approval. Developing market facing data during development can impact product label, patient access and overall product success.
Brian Carey will serve as a panelist, with Marc Samuels, Managing Partner of HillCo HEALTH.
Wednesday, June 26, 3:30 - 4:30 p.m.
Press Conference/Audio Conference on SCOTUS Ruling on DNA Patents
DIA will convene a press conference to discuss the recent Supreme Court ruling on DNA patents, the complexity of DNA patents and the uncertainties raised by the ruling, as well as future implications for the biotech and pharmaceutical sectors.
Hathaway Russell will serve on a panel of patent and scientific/business experts.
Thursday, June 27, 9:00-10:15 a.m.
“The Not So Rare Challenge that Faces Rare Disease Development: Demonstrate Value”
Increased development of orphan products has changed how payer regulators view rare diseases. Rare disorders can now have several products FDA indicated for use; this requires that developers demonstrate the value of these rare disease products.
Igor Gorlach will serve as a panelist, with Jim Long, Co-Founder and Principal of BioSolutia.
DIA (Drug Information Association) is a science driven, non-profit membership organization whose mission is to serve as a neutral forum for information exchange to facilitate innovation and advances in medical product development. The organization works with the pharmaceutical, biotechnology, devices and diagnostics sectors, and covers the full spectrum of the product life cycle from development to access.